Erythrocytes enhance the immunogenicity of oral vaccination with gamma irradiated influenza virus: increasing the dose of irradiation results in a significant diminution of lung IgA response.
Previous studies have demonstrated that the ability of gamma-irradiated whole influenza virus to prime for specific anti-influenza antibody responses was dramatically enhanced when delivered in a complex with chicken red blood cell ghosts (cRBC). The purpose of this study was to investigate the effect of increasing the dose of gamma irradiation used to inactivate A/Queensland/6/72 virus on the ability of the virus-cRBC complex to prime for specific influenza responses. Spleen cell proliferation studies confirmed the enhancing effect of the cRBC carrier for oral vaccination with irradiated virus. Cells from mice vaccinated with 30 kGy-irradiated virus only did not respond to influenza stimulation in vitro, whereas cells from mice vaccinated with irradiated virus+cRBC showed significant increases in proliferation to antigen exposure. No significant antibody response or challenge virus clearance was observed in mice orally vaccinated with irradiated (13.1 or 30 kGy) virus alone, even when the dose was increased significantly. Oral vaccination with live virus (+/-cRBC) primed for significant influenza specific IgA responses in the lungs, in addition to IgG responses in the lungs and sera. The dose of irradiation used to inactivate the virus was found to be critical to the profile of antibody response when the virus was delivered in a complex with cRBC. Oral vaccination of Swiss mice with 13.1 or 30 kGy virus (+cRBC) primed for significant serum and lung IgG responses. Lung IgA responses for 13.1 kGy+cRBC vaccinated mice were detected, but 30 kGy+cRBC vaccinated Swiss and CBA/H mice had no significant lung IgA response. The abrogation of IgA response, however, did not lessen the clearance of live challenge virus in outbred mice, suggesting a primary role for IgG and/or CTL response in the control of influenza virus infection post oral vaccination. To ensure direct comparison of virus alone and virus+cRBC treatments, the concentration of virus complexed to the cRBC was determined.
Lidbury
B A
BA
Australian Institute of Mucosal Immunology, Royal Newcastle Hospital, N.S.W., Australia.
Grissell
T V
TV
Sizer
P J
PJ
Pang
G T
GT
Clancy
R
R
Cripps
A W
AW
D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000917:Antibody Formation / Q000528:radiation effects; D002478:Cells, Cultured; D004912:Erythrocytes / Q000502:physiology*; D005720:Gamma Rays; D007070:Immunoglobulin A / Q000096:biosynthesis*; D007252:Influenza Vaccines / Q000276:immunology*; D008168:Lung / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009975:Orthomyxoviridae / Q000528:radiation effects*; D014611:Vaccination
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007252:Influenza Vaccines